Topical DHEA Against Vaginal Atrophy

Inclusion Criteria:

- Postmenopausal women (non hysterectomized or hysterectomized)

- Women between 40 and 75 years of age

- Willing to participate in the study and sign an informed consent

- Women having a low maturation index (no greater part of guidance than 5% of
superficial cells on vaginal smear)

- Women having a vaginal pH above 5

- Women who have self-identified at least one moderate to severe symptoms of
vulvovaginal atrophy

Exclusion Criteria:

- Undiagnosed abnormal genital bleeding

- Hypertension equal to or above 160/95 mm Hg or not controlled by standard therapy

- The administration of any investigational drug within 30 days of screening visit

- Endometrial hyperplasia at biopsy performed at screening or endometrial cancer

- Use of estrogens/progestins products (vaginal, oral, pellet, transdermal, etc) in the
4 weeks to 6 months (depending on the product used) prior study entry